LENSAR Spinoff Completed
PDL BioPharma Inc. announced the completion of the previously announced spinoff of its femtosecond laser system business LENSAR. Beginning Oct. 2, LENSAR shares began “regular way” trading on the Nasdaq composite exchange.
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of preexisting or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist surgeons in obtaining better outcomes, efficiency, and reproducibility through advanced imaging and procedure planning.
LATEST NEWS
- Infleqtion, Thorlabs Partner on Quantum Commercialization: Briefs: 10/4/24
Oct 4, 2024
- Valens Semiconductor Develops MIPI A-PHY-Compliant Chipsets
Oct 4, 2024
- OLED Tech Provides Optogenetic Light Source for Cochlear Implants
Oct 3, 2024
- NTT and NEC Enable Sensing in IOWN All-Photonics Network
Oct 3, 2024
- Polar Light, Finetech Partner on MicroLED Tech for Advanced Applications
Oct 2, 2024
- TOPTICA Photonics Appoints Two to C-Suite Positions: People in the News: 10/2/24
Oct 2, 2024
- European Initiative's Quantum Sensors Aim to Deliver Climate Insights
Oct 1, 2024
- IonQ Awarded $54.5M Contract with U.S. Air Force Research Lab
Oct 1, 2024